Featured Research

from universities, journals, and other organizations

Combination therapies a cost-effective alternative for treating visceral leishmaniasis

Date:
September 16, 2013
Source:
Institute of Tropical Medicine Antwerp
Summary:
Visceral leishmaniasis is the second-deadliest parasitic disease after malaria. Each year, thousands fall victim among poor and marginalised populations in low-income countries. A new study is the first to detail the economic aspects of the disease in India, Nepal and Sudan.

Visceral leishmaniasis is the second-deadliest parasitic disease after malaria. Each year, thousands fall victim among poor and marginalised populations in low-income countries. Filip Meheus is the first to detail the economic aspects of the disease in India, Nepal and Sudan. On 16 September, Meheus will receive a PhD title at the University of Nijmegen for his research at the Institute of Tropical Medicine (ITM) in Antwerp.

Related Articles


Visceral leishmaniasis has become harder to control, because current treatments increasingly fail (like in Nepal with resistance to the drug miltefosine). Meheus shows that combination therapies (the use of multiple drugs) is a cost-effective alternative to the current first-line treatments. This is mainly due to the shorter duration of treatment and the lower cost of the drugs used for combination therapies.

Combination therapies would also alleviate the enormous economic damage the disease causes in families and relieve the workload in hospitals. However, additional efforts are needed to further drop prices of some drugs (like liposomal amphotericin B) and diagnose and treat patients more quickly.

"This disease wrecks patients twice, both physically and financially. The study results offer tools to assist them better, even where the needs are huge and the means limited," said Meheus.

The full study can be accessed here: http://www.itg.be/internet/dl/EconomicAnalysisOfVLControl-FilipMeheus.pdf


Story Source:

The above story is based on materials provided by Institute of Tropical Medicine Antwerp. Note: Materials may be edited for content and length.


Cite This Page:

Institute of Tropical Medicine Antwerp. "Combination therapies a cost-effective alternative for treating visceral leishmaniasis." ScienceDaily. ScienceDaily, 16 September 2013. <www.sciencedaily.com/releases/2013/09/130916090842.htm>.
Institute of Tropical Medicine Antwerp. (2013, September 16). Combination therapies a cost-effective alternative for treating visceral leishmaniasis. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2013/09/130916090842.htm
Institute of Tropical Medicine Antwerp. "Combination therapies a cost-effective alternative for treating visceral leishmaniasis." ScienceDaily. www.sciencedaily.com/releases/2013/09/130916090842.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins